FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Granulomatosis with Polyangiitis
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis
• Small Lymphocytic Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

SUPPL AP for RITUXAN (RITUXIMAB)